We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
-3.14%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$52.8B
AUM Growth
-$1.34B
Cap. Flow
+$1.39B
Cap. Flow %
2.62%
Top 10 Hldgs %
12%
Holding
4,607
New
780
Increased
956
Reduced
789
Closed
1,336

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$532M
2
WFC icon
Wells Fargo
WFC
+$480M
3
V icon
Visa
V
+$435M
4
VZ icon
Verizon
VZ
+$320M
5
AVGO icon
Broadcom
AVGO
+$273M

Sector Composition

Rank Sector Weight
1 Financials 18.66%
2 Technology 16.35%
3 Healthcare 16.13%
4 Consumer Discretionary 11.2%
5 Industrials 7.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HRZN icon
2826
Horizon Technology Finance
HRZN
$290M
$421K ﹤0.01%
30,250
-13,822
-31% -$209K
TGI
2827
DELISTED
Triumph Group
TGI
$421K ﹤0.01%
16,666
-10,481
-39% -$233K
SSTI icon
2828
SoundThinking
SSTI
$109M
$419K ﹤0.01%
15,104
+1,897
+14% +$51.7K
MITA
2829
DELISTED
Coliseum Acquisition Corp. Class A Ordinary Share
MITA
$419K ﹤0.01%
43,159
AGBAW
2830
CALL
DELISTED
AGBA Acquisition Ltd Warrant
AGBAW
$418K ﹤0.01%
37,464
LXFR icon
2831
Luxfer Holdings
LXFR
$457M
$416K ﹤0.01%
24,755
-2,285
-8% -$40.4K
VNQ icon
2832
Vanguard Real Estate ETF
VNQ
$39.8B
$416K ﹤0.01%
+3,840
New +$406K
CDMO
2833
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$416K ﹤0.01%
+20,482
New +$417K
FCG icon
2834
First Trust Natural Gas ETF
FCG
$628M
$414K ﹤0.01%
+17,003
New +$357K
AMRN
2835
Amarin Corp
AMRN
$297M
$412K ﹤0.01%
+6,254
New +$413K
FRPT icon
2836
Freshpet
FRPT
$3.05B
$411K ﹤0.01%
4,005
-29,463
-88% -$2.77M
GLSI icon
2837
Greenwich LifeSciences
GLSI
$191M
$410K ﹤0.01%
20,905
+3,186
+18% +$64.4K
USIO icon
2838
Usio Inc
USIO
$53.8M
$408K ﹤0.01%
113,632
+11,539
+11% +$40.2K
FRMM
2839
Forum Markets
FRMM
$70.5M
$407K ﹤0.01%
41
-38
-48% -$437K
NVO
2840
Novo Nordisk
NVO
$227B
$407K ﹤0.01%
7,332
-1,746
-19% -$89.6K
KROS icon
2841
Keros Therapeutics
KROS
$197M
$406K ﹤0.01%
7,468
+1,741
+30% +$89.4K
RLI icon
2842
RLI Corp
RLI
$6.02B
$406K ﹤0.01%
+7,340
New +$387K
SLVR
2843
DELISTED
SilverSPAC Inc. Class A Ordinary Share
SLVR
$406K ﹤0.01%
41,988
ZYME icon
2844
Zymeworks
ZYME
$1.61B
$405K ﹤0.01%
+61,735
New +$550K
HSKA
2845
DELISTED
Heska Corp
HSKA
$405K ﹤0.01%
2,928
+1,013
+53% +$143K
RFL icon
2846
Rafael Holdings
RFL
$106M
$404K ﹤0.01%
163,379
-15,051
-8% -$51.6K
HRTG icon
2847
Heritage Insurance Holdings
HRTG
$902M
$403K ﹤0.01%
56,534
-169,260
-75% -$1.05M
PRPC.WS
2848
CALL
DELISTED
CC Neuberger Principal Holdings III Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
PRPC.WS
$401K ﹤0.01%
40,743
NBN icon
2849
Northeast Bank
NBN
$1.05B
$398K ﹤0.01%
11,695
-7,662
-40% -$279K
ICU icon
2850
SeaStar Medical
ICU
$13.3M
$396K ﹤0.01%
156

Similar funds

Marshall Wace's Q1 2022 Portfolio in Review

As of Q1 2022, Marshall Wace held 4,607 positions worth $52.8B, down 2.5% from $54.2B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Marshall Wace's Q1 2022 filing shows 780 new, 956 increased, 789 reduced and 1,336 closed positions. Its largest new stake was Agilent Technologies: 1,082,487 shares worth $143M. The largest sale was Microsoft, an estimated $547M.

By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 16% a quarter earlier, followed by Technology and Healthcare.

  • Marshall Wace's largest Q1 2022 buy was Agilent Technologies: 1,082,487 shares worth $143M.
  • Marshall Wace added most to Merck in Q1 2022, an estimated $532M increase.
  • Marshall Wace's biggest Q1 2022 reduction was Microsoft, cutting an estimated $547M.
  • Marshall Wace fully exited Elevance Health in Q1 2022, selling an estimated $226M.
  • Marshall Wace's ten largest holdings make up 12% of its $52.8B portfolio in Q1 2022.
  • Marshall Wace opened 780 new positions and closed 1,336 in Q1 2022.
  • Marshall Wace's portfolio value fell 2.5% quarter-over-quarter to $52.8B.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.